Once a staple in American households, direct to consumer companies like Tupperware and Avon are seeing significant shake ups after filing for bankruptcy.

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

Revenue from domestic retained business increased by 1.2% despite the inclusion of Companys flagship brand ... Consumer Healthcare Business of the Company into Companys wholly owned subsidiary ...

Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and Dulcolax.

French pharma giant Sanofi is selling off its consumer healthcare business Opella ... of over-the-counter medicines and dietary supplements and includes well-known brands like Allegra (fexofenadine) ...

Sanofi has entered exclusive negotiations to sell a 50% controlling stake in its consumer health business ... Opella, which houses brands including Allegra, generated sales of $5.7 billion ...

Sanofi saw revenues for its consumer health arm, Opella, grow 7.9%. Earlier this week, Sanofi confirmed it had entered exclusive negotiations with U.S. private equity firm Clayton, Dubilier & Rice ...

Sanofi’s entrenched rare-disease drug, consumer, and vaccine franchises create added layers of competitive advantages, stemming from efficient scale in some rare-disease drugs, brand power in ...